AstraZeneca to Use Ingenuity's IPA Platform
Ingenuity Systems said this week that it has signed a multi-year deal with AstraZeneca. Financial details were not disclosed.
Under the terms of the agreement, the pharmaceutical firm will use the Ingenuity Pathway Analysis platform in its research and target discovery programs in order to build biological models and analyze and share data.
"IPA can support a wide range of research objectives across our target and biomarker discovery programs — such as providing insight into target efficacy, drugability, and increasingly, toxicity," Ian Dix, principal informatics scientist at AstraZeneca, said in a statement.
"The richness and contextual nature of the content is important for us because it provides a detailed view of the molecular basis of disease," which is critical for the drug discovery decision-making process, he said.
Golden Helix to Provide Bioinformatics Support for Agilent CNV Arrays
Golden Helix will provide software tools and services for Agilent’s expanding menu of copy number variation microarrays, the companies said this week.
Agilent markets its own microarray analysis software under the GeneSpring and DNA Analytics brands, and the company said it plans to eventually develop the informatics tools necessary to run and analyze data from copy number association studies. However, a company official told BioInform sister publication BioArray News this week that the arrangement with Golden Helix will immediately provide customers with the software and services required to begin these studies.
As part of the deal, Golden Helix said in a statement that its SNP & Variation Suite has been "modified to directly import, analyze, and visualize Agilent’s genome-wide copy number data, including association studies, data prep, quality assurance, interaction analyses, study review, and predictive modeling for research purposes."
Bozeman, Mont.-based Golden Helix has also expanded its analytic service offering to incorporate studies based on Agilent’s CGH/CNV microarray data.
The companies did not discuss any financial components of the deal, but pledged to engage in co-marketing activities that will become more frequent as customers progress with their copy number association studies.